A metabolite-based machine learning approach to diagnose Alzheimer’s-type dementia in blood: Results from the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Abstract
INTRODUCTION Machine learning (ML) may harbor the potential to capture the metabolic complexity in Alzheimer’s Disease (AD). Here we set out to test the performance of metabolites in blood to categorise AD when compared to CSF biomarkers.
METHODS This study analysed samples from 242 cognitively normal (CN) people and 115 with AD-type dementia utilizing plasma metabolites (n=883). Deep Learning (DL), Extreme Gradient Boosting (XGBoost) and Random Forest (RF) were used to differentiate AD from CN. These models were internally validated using Nested Cross Validation (NCV).
RESULTS On the test data, DL produced the AUC of 0.85 (0.80-0.89), XGBoost produced 0.88 (0.86-0.89) and RF produced 0.85 (0.83-0.87). By comparison, CSF measures of amyloid, p-tau and t-tau (together with age and gender) produced with XGBoost the AUC values of 0.78, 0.83 and 0.87, respectively.
DISCUSSION This study showed that plasma metabolites have the potential to match the AUC of well-established AD CSF biomarkers in a relatively small cohort. Further studies in independent cohorts are needed to validate whether this specific panel of blood metabolites can separate AD from controls, and how specific it is for AD as compared with other neurodegenerative disorders
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
IMI has
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
On request to the data repository’s
Subject Area
- Addiction Medicine (336)
- Allergy and Immunology (664)
- Anesthesia (178)
- Cardiovascular Medicine (2600)
- Dermatology (218)
- Emergency Medicine (391)
- Epidemiology (12139)
- Forensic Medicine (10)
- Gastroenterology (752)
- Genetic and Genomic Medicine (4035)
- Geriatric Medicine (380)
- Health Economics (671)
- Health Informatics (2607)
- Health Policy (995)
- Hematology (359)
- HIV/AIDS (833)
- Medical Education (397)
- Medical Ethics (109)
- Nephrology (426)
- Neurology (3804)
- Nursing (208)
- Nutrition (567)
- Oncology (1991)
- Ophthalmology (578)
- Orthopedics (235)
- Otolaryngology (303)
- Pain Medicine (250)
- Palliative Medicine (73)
- Pathology (470)
- Pediatrics (1100)
- Primary Care Research (443)
- Public and Global Health (6473)
- Radiology and Imaging (1379)
- Respiratory Medicine (866)
- Rheumatology (395)
- Sports Medicine (337)
- Surgery (438)
- Toxicology (52)
- Transplantation (185)
- Urology (165)